European Blood Pressure Intensive Control After Stroke
- Conditions
- Transient Ischemic AttackIschemic Stroke
- Interventions
- Other: anti-hypertensive, home blood pressure measurement, telemonitoring and medication titrationOther: Standard of Care Blood Pressure Management with Antihypertensives
- Registration Number
- NCT04647292
- Lead Sponsor
- University College Dublin
- Brief Summary
Stroke is the third most common cause of death worldwide and the leading cause of disability. High blood pressure is an important risk factor for stroke. Lowering a person's blood pressure reduces the risk of future stroke or heart attack, and current guidelines recommend treatment to a target of \<130mmHg for secondary prevention.
Home blood pressure measurement and telemonitoring are acceptable to patients, but there is uncertainty over the use of out of office blood pressure measurements in stroke patients in guidelines.
This is a study designed to establish the feasibility of a larger clinical trial, comparing home blood pressure monitoring, telemonitoring and medication titration with standard care. The study hypothesis is that home BP measurement and telemonitoring with medication titration may lead to improved BP control compared to standard of care clinical practice.
- Detailed Description
Background:
Stroke is the third leading cause of global death, the leading cause of acquired disability and contributes substantially to dementia, cognitive decline, and healthcare costs. Global epidemiological studies such as INTERSTROKE and the Global Burden of Disease study estimated that hypertension is the leading modifiable risk factor for stroke, with a population attributable risk of approximately 50%. Recurrent vascular events (stroke, coronary events, vascular death) cause significant morbidity in ischaemic stroke survivors, affecting approximately 30% at 5 years.
High rates of failure to achieve guideline BP targets (\<130mmHg) are reported in clinical practice for patients following ischaemic stroke or TIA. Home blood pressure measurement and telemonitoring is recognised as acceptable to patients from previous studies, and some trials have noted a significant reduction in BP at 12 months. The latest ESO guidelines note continued uncertainty over the use of out-of-office blood pressure measurements for adult patients with ischaemic stroke or TIA due to insufficient data.
This trial will recruit patients with recent stroke/TIA events with systolic BP ≥140 mmHg and randomise them to standard of care or home BP monitoring with telemonitoring and medication titration. The study hypothesis is that home BP measurement and telemonitoring with medication titration may lead to improved BP control compared to standard of care clinical practice.
Aim:
The aim is to conduct an initial pilot randomised trial in Ireland and European centres involved in the European Stroke Organisation Trials Alliance. This feasibility study will assess key design aspects and establish trial governance, data management, and procedures in preparation for a larger definitive trial.
Methods:
Design: Prospective, open-label, blinded endpoint assessed (PROBE) randomised, parallel group pilot/feasibility clinical trial, comparing BP patient self-measurement and telemonitoring with office-based monitoring (standard of care) for improved BP control after ischaemic stroke/TIA.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 142
- Age ≥40
- Ischaemic stroke1, high-risk TIA, proven by imaging (brain CT/MRI)
- Living at home and independent (walking without the aid of another person, but may have some help for daily activities)
- SBP≥140mmHg at entry (average of 2 measures, seated, in the same arm, after resting alone in office for 10 minutes)
- Qualifying event between 30 days and 1 year of randomisation
- Glomerular filtration rate (eGFR) greater than or equal to 50ml/min/m2 (within 3 months of randomisation)
- Medically-stable and capable of participating in a randomised trial, including home BP measures, in the opinion of the study physician
- Willing to provide informed consent (no surrogate consent will apply)
- SBP <110mmHg after 3 minutes of standing or other contra-indication to intensive SBP lowering in opinion of treating clinician (eg. Orthostatic symptoms, syncope or pre syncope, recurrent falls)
- Qualifying stroke due to intracerebral haemorrhage (ICH), cardio-embolism or other defined causes (eg. dissection, endocarditis, other specified)
- Severe stenosis or occlusion of large cranio-cervical artery (>70% stenosis/occlusion of cervical carotid, vertebral, or Circle of Willis artery)
- Unlikely to comply with study procedures due to severe or fatal comorbid illness (eg. dementia, active malignancy, severe frailty) or other factor (eg. inability to travel)
- Pregnancy or breastfeeding
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Home Blood Pressure Measurement, Telemonitoring and Medication titration anti-hypertensive, home blood pressure measurement, telemonitoring and medication titration Medication titration to guideline SBP \<130mmHg Control Group: Standard of Care Blood Pressure Management Standard of Care Blood Pressure Management with Antihypertensives Standard of Care Management by GP/physician to SBP \<130mmHg by current European Stroke Organisation, American Stroke Association and UK NICE guidelines
- Primary Outcome Measures
Name Time Method Difference in mean SBP 12 months (or last trial visit) The difference in mean SBP between both groups, at 12 months (or last trial visit)
- Secondary Outcome Measures
Name Time Method Number of pre-specified adverse events 12 months (or last trial visit) Time in guideline-based target range 12 months (or last trial visit) Proportion of SBP measures \<130 during trial participation
Time to first composite major adverse cardiovascular event (MACE), and to each component of the composite, stratified as fatal, non-fatal and total 12 months (or last trial visit) MACE defined as all recurrent stroke, myocardial infarction, cardiac arrest
Time taken to reach target 12 months (or last trial visit) Time taken to reach target SBP\<130mmHg
Number of patients lost to follow-up 12 months (or end of trial visit) Difference in mean diastolic blood pressure (DBP) between groups 12 months (or last trial visit) All-cause fatality 12 months (or last trial visit) Change in SBP/DBP from baseline to end-of-trial 12 months (or last trial visit) Proportions of patients assigned to each arm successfully reaching guideline-based target (SBP<130mmHg) at end of trial visit 12 months (or last trial visit) Number of serious adverse events 12 months (or last trial visit) Difference in proportion of patients with serious adverse events
Comparison of disability in each intervention arm assessed by modified Rankin score 12 months (or last trial visit) Shift analysis and proportion with no, mild, or moderate disability, Rankin score 0-3
Change in health related quality of life 12 months (or last trial visit) Change in EQ5D-5L score (5 domains assessed with scores of 1-5 ranking the severity of impairment, with higher scores indicating poorer quality of life) at last follow-up compared with baseline
Time required per follow up visit 12 months (or last trial visit) Change in cognition 12 months (or last trial visit) Change in Montreal cognitive assessment score (range 0-30) at last follow-up compared with baseline score. A lower score indicates greater cognitive impairment.
Qualitative patient feedback obtained via workshops and questionnaires 12 months (or last trial visit) Number of dose-titrations required 12 months (or last trial visit)
Trial Locations
- Locations (1)
Mater Misericordiae University Hospital
🇮🇪Dublin, Ireland